Vilazodone

From Self-sufficiency
Jump to: navigation, search
Vilazodone
File:Vilazodone.png
Systematic (IUPAC) name
5-(4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl)benzofuran-2-carboxamide
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
  • Uncontrolled
Pharmacokinetic data
Biological half-life 20-24 hours
Identifiers
CAS Number 163521-12-8
ATC code none
PubChem CID 6918313
Chemical data
Formula C26H27N5O2
Molar mass 441.524 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Vilazodone (EMD-68,843, SB-659,746-A) is an antidepressant which is currently under development by Clinical Data for the treatment of major depressive disorder, and as of 2009 has completed two phase III clinical trials with positive results.[1] In the United States, an NDA was submitted on March 23rd, 2010 and was accepted by the FDA on May 21, 2010. Vilazodone is currently under standard review by the FDA with a PDUFA date of January 22, 2011, and if approved, will likely become available in the United States sometime next year.[2][3]

Pharmacology

Vilazodone acts as a serotonin reuptake inhibitor (IC50 = 0.2 nM) and 5-HT1A receptor partial agonist (IC50 = 0.5 nM; IA = ~60-70%).[4][5] It has negligible affinity for other serotonin receptors such as 5-HT1D, 5-HT2A, and 5-HT2C.[4][5]

Efficacy and tolerability

According to an eight-week, randomized, double-blind, placebo-controlled trial, vilazodone was reported to elicit an antidepressant response after 1 week of treatment. After 8 weeks, subjects assigned to vilazodone experienced a significantly higher response rate than the group given placebo. At a dose of 40 mg per day, it's considered to be well tolerated and reported adverse effects ranged from mild to moderate in intensity; side effects included diarrhea, nausea, and somnolence.[6]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
Azapirones: Buspirone • Gepirone • Tandospirone; Others: Flesinoxan • Oxaflozane
H1 Antagonists
Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)


35px This drug article relating to the nervous system is a stub. You can help ssf by expanding it.
  1. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. ↑ "Clinical Data, Inc. - Clinical Data, Inc. Announces Positive Results from Second Phase III Trial of Vilazodone for Depression". 
  3. ↑ "Clinical Data, Inc. - Clinical Data, Inc. Submits New Drug Application for Vilazodone for the Treatment of Major Depressive Disorder". 
  4. ↑ 4.0 4.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  5. ↑ 5.0 5.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  6. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Vilazodone&oldid=22724"